Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis.
Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis. Nuclera has since grown to fifty-seven employees across two continents as the Company delivers on its founders’ vision to make biology accessible to everyone through desktop bioprinting. With desktop bioprinting, researchers and scientists will be empowered to take control of biology through streamlined access to a next-day supply of proteins and genes.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 6, 2022 | Series B | $15.50M | 1 | Verve Ventures | — | Detail |
Feb 2, 2022 | Series B | $42.50M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Verve Ventures | Yes | Series B |
RT Partners | — | Series B |